One-third of cervical cancer patients are still diagnosed at advanced stages. The five-year survival rate is decreased in about 50% of advanced stage cervical cancer patients worldwide, and the clinical outcomes are remarkably varied and difficult to predict. | MicroRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer